We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EirGenix

News List

Sandoz seeks EMA approval for EirGenix’s trastuzumab biosimilar Pharmaceutical-Business-Review
December 24, 2021
Trastuzumab is a monoclonal antibody intended to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast and metastatic gastric cancers.
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar prnasia
March 25, 2021
In a press conference today, EirGenix, Inc. announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint.
Sandoz signs cancer drug deal with EirGenix pharmaceutical-technology
May 05, 2019
Sandoz has signed an agreement with EirGenix for the commercialisation of a trastuzumab biosimilar.